Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amsacrine: a review.

P A Cassileth, R P Gale

    Leukemia Research
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Amsacrine shows significant antitumor activity in acute leukemias and lymphomas. This acridine derivative offers improved remission rates for patients with acute myelogenous leukemia, even those resistant to other treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.

    Leukemia·2003
    Same author

    Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

    Blood·2000
    Same author

    Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.

    Blood·2000
    Same author

    Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group.

    Leukemia·2000
    Same author

    Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).

    Leukemia·2000
    Same author

    Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) Study.

    American journal of clinical oncology·2000
    Same journal

    A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.

    Leukemia research·2026
    Same journal

    FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study.

    Leukemia research·2026
    Same journal

    CD244 modulates bone marrow infiltrating CD8<sup>+</sup> T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.

    Leukemia research·2026
    Same journal

    Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.

    Leukemia research·2026
    Same journal

    Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

    Leukemia research·2026
    Same journal

    CRS and ICANS as class-level adverse event for CD20 ×CD3 bispecific T-cell engagers: A Bayesian analysis of a nationwide database.

    Leukemia research·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Amsacrine, an acridine derivative, has demonstrated antitumor properties.
    • Its efficacy is established in hematological malignancies like acute leukemias and lymphomas.
    • Amsacrine shows limited effectiveness against solid tumors.

    Purpose of the Study:

    • To evaluate the antitumor activity of amsacrine.
    • To assess its role in treating acute leukemias and lymphomas.
    • To determine its potential in improving remission rates for acute myelogenous leukemia.

    Main Methods:

    • Clinical evaluation of amsacrine's efficacy.
    • Comparative analysis against standard chemotherapeutic agents (cytarabine, daunorubicin).
    • Assessment in patients refractory to existing treatments.

    Related Experiment Videos

    Main Results:

    • Amsacrine is effective in acute leukemias and lymphomas.
    • It demonstrates comparable efficacy to cytarabine and daunorubicin in acute myelogenous leukemia.
    • Complete remissions were achieved in patients resistant to standard therapies.

    Conclusions:

    • Amsacrine is a valuable addition to the treatment of acute myelogenous leukemia.
    • It offers potential for enhanced remission rates and duration.
    • Its use is recommended for patients refractory to conventional treatments.